MOROCCO—The Ministry of Health and Social Protection and the Ministry of Industry, Morocco, have signed a public-private partnership (PPP) with Regen Lab to promote the development of regenerative medicines and clinical trials for Morocco and Africa.
The new PPP arrangement involves Regen Lab, a Swiss medical technology company specializing in the research, development, registration, manufacturing, and commercialization of proprietary tissue engineering products.
The Moroccan Ministry of Industry, the Dassault Systèmes group (3DS), Baylor College of Medicine (Texas, USA), and the Moroccan Therapeutic Society (SOTHEMA, la Société Thérapeutique Marocaine) will also be involved in the PPP.
The PPP derives to create a fully integrated global operational structure dedicated to the deployment of regenerative medicine in Morocco and eventually widely in Africa.
With strong governance and sustainable funding mechanisms, this partnership will focus on developing international regulatory standards that consider patient diversity.
The PPP also considers the development of clinical research on diseases with high mortality rates (e.g., heart disease and cancers).
Additionally, it will launch a fully integrated platform, called “InSiDDe”, meeting the high standards of FDA-registered GLP (Good Laboratory Practice) and registered with the FDA, for the development of accessible medicines.
Moreover, it will also integrate digital technologies into clinical trials («in silico clinical trial») to better measure the effectiveness of treatment, capture the heterogeneity of patient populations and adopt digital tools as well as cutting-edge technologies, including remote diagnosis.
The PPP will ensure the training of medical staff in cutting-edge technologies.
It will also Leverage 3DS technologies and the network of all our entities to attract human capital to Africa.
The PPP also seeks to develop clinical research in Morocco through partnerships with university hospitals and eventually build the first clinical research hospital in compliance with US standards.
Prof. Khalid Ait Taleb, Minister of Health and Social Protection said, “We are proud to enter into such an agreement with highly recognized players in the healthcare sector.”
The Minister acknowledged that the new partnership represented a tremendous lever to accelerate innovation in numerous therapeutic areas for the benefit of Moroccan public health, and ultimately to create a solid biotechnology industry on our territory.
Importantly as the lead in the partnership, Regen Lab will focus on; innovation (Laboratory and clinical studies), and the manufacture of tissue-engineered medical devices.
Regen Labs has also been tasked with drug delivery and personalized medicine (oncology and preventive surgery), and the communication and dissemination of medical technologies.
Antoine Turzi, CEO of Regen Lab Group emphasized that Regen Lab was honored to be part of this ecosystem of prestigious public and private players, and we are proud to be able to bring our expertise in regenerative medicine to the Moroccan public health authorities.
“The aim of this high-quality scientific collaboration is to produce and market new medical technologies for the benefit of Moroccan and, more broadly, African patients,” highlighted Turzi.
Finally, this partnership will help to create interactions with players in the ecosystem in the United States.
Particularly, Long Island University, with which Regen Lab and 3DS signed a partnership agreement at the beginning of June to set up an industrial innovation accelerator dedicated to regenerative medicine and tissue engineering.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
